Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A delayed chemically induced tumorigenesis in Brca2 mutant mice.

Yan DH, Wen Y, Su LK, Xia W, Wang SC, Zhang S, Gan L, Lee DF, Spohn B, Frey JA, Hortobagyi GN, Hung MC.

Oncogene. 2004 Mar 11;23(10):1896-901.

PMID:
14981540
2.
3.

Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice.

Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, Wiseman RW, Medina D.

Mol Carcinog. 1994 Mar;9(3):175-83.

PMID:
8142019
4.

Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene.

McAllister KA, Bennett LM, Houle CD, Ward T, Malphurs J, Collins NK, Cachafeiro C, Haseman J, Goulding EH, Bunch D, Eddy EM, Davis BJ, Wiseman RW.

Cancer Res. 2002 Feb 15;62(4):990-4.

5.

Environmental carcinogens and p53 tumor-suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis.

Medina D, Ullrich R, Meyn R, Wiseman R, Donehower L.

Environ Mol Mutagen. 2002;39(2-3):178-83.

PMID:
11921187
6.

Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice.

Cheung AM, Elia A, Tsao MS, Done S, Wagner KU, Hennighausen L, Hakem R, Mak TW.

Cancer Res. 2004 Mar 15;64(6):1959-65.

7.

Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis.

Cheung AM, Hande MP, Jalali F, Tsao MS, Skinnider B, Hirao A, McPherson JP, Karaskova J, Suzuki A, Wakeham A, You-Ten A, Elia A, Squire J, Bristow R, Hakem R, Mak TW.

Cancer Res. 2002 Nov 1;62(21):6194-204.

8.
9.

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.

Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A.

Cancer Res. 2005 Sep 15;65(18):8166-73.

10.

Absence of Ras mutations in rat DMBA-induced mammary tumors.

Samuelson E, Nilsson J, Walentinsson A, Szpirer C, Behboudi A.

Mol Carcinog. 2009 Feb;48(2):150-5. doi: 10.1002/mc.20464.

PMID:
18649354
11.
12.

Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.

Murphy KL, Kittrell FS, Gay JP, Jäger R, Medina D, Rosen JM.

Oncogene. 1999 Nov 11;18(47):6597-604.

13.

Induction by 7,12-dimethylbenz(a)anthracene of molecular and biochemical alterations in transformed human mammary epithelial stem cells, and protection by N-acetylcysteine.

De Flora S, Scarfì S, Izzotti A, D'Agostini F, Chang CC, Bagnasco M, De Flora A, Trosko JE.

Int J Oncol. 2006 Sep;29(3):521-9.

PMID:
16865267
14.

Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency.

Hollander MC, Kovalsky O, Salvador JM, Kim KE, Patterson AD, Haines DC, Fornace AJ Jr.

Cancer Res. 2001 Mar 15;61(6):2487-91.

15.
16.

Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation.

Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A.

Nat Genet. 1997 Dec;17(4):423-30.

PMID:
9398843
17.

Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.

Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR.

Cancer Res. 2005 Nov 15;65(22):10145-8. Erratum in: Cancer Res. 2006 Jan 1;66(1):599.

18.

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A.

Cancer Biol Ther. 2005 Sep;4(9):934-6. Epub 2005 Sep 1.

PMID:
16251802
19.

Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function.

Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW.

Cancer Res. 1999 Sep 1;59(17):4276-84.

20.

Supplemental Content

Support Center